Aflibercept Biosimilars Market Size, Share, Growth, and Industry Analysis, By Type (2mg,8mg), By Application (Hospitals,Clinics,Others), Regional Insights and Forecast to 2035

Aflibercept Biosimilars Market Overview

The global Aflibercept Biosimilars Market is forecast to expand from USD 10289.95 million in 2026 to USD 10434.01 million in 2027, and is expected to reach USD 11148.67 million by 2035, growing at a CAGR of 1.4% over the forecast period.

The Aflibercept Biosimilars Market is driven by the increasing prevalence of retinal disorders, with over 196 million people globally affected by age-related macular degeneration (AMD) in 2023, projected to reach 288 million by 2040. Diabetic retinopathy impacts more than 103 million individuals worldwide, while diabetic macular edema (DME) affects nearly 21 million patients. Aflibercept 2 mg injections are administered every 4 to 8 weeks, translating into 6 to 12 injections annually per patient. Patent expirations between 2023 and 2025 have opened access to biosimilar development pipelines across 15+ countries. More than 20 biosimilar candidates are in clinical or regulatory stages globally.

The USA accounts for nearly 38% of global anti-VEGF treatment procedures, with over 7 million intravitreal injections administered annually. Approximately 11 million Americans suffer from AMD, including 1.5 million with advanced forms. Diabetic retinopathy affects 9.6 million adults in the United States, and DME impacts nearly 750,000 patients. The FDA approved aflibercept in 2011, and biosimilar regulatory pathways under the Biologics Price Competition and Innovation Act have enabled over 40 biosimilar approvals across therapeutic categories. In 2024, at least 3 aflibercept biosimilar candidates were under FDA review, with manufacturing facilities exceeding 200,000 liters of biologics capacity.

What is Aflibercept Biosimilars?

Aflibercept Biosimilars are biologic medicines developed to be highly similar to the original aflibercept reference product used in the treatment of retinal disorders such as age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy. These biosimilars are administered through intravitreal injections and are designed to inhibit vascular endothelial growth factor (VEGF), helping reduce abnormal blood vessel growth and vision loss. Aflibercept biosimilars provide cost-effective alternatives to branded biologic therapies while maintaining comparable safety, efficacy, and quality standards.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Over 65% of AMD patients require anti-VEGF therapy, while 58% of diabetic patients develop retinal complications; 72% of ophthalmologists prefer cost-effective biologics, and 48% of healthcare systems prioritize biosimilars for formulary inclusion.
• Major Market Restraint: Approximately 35% of physicians express concerns over interchangeability, 42% cite immunogenicity risks, 28% report switching hesitancy, and 31% of payers maintain restricted substitution policies.
• Emerging Trends: Nearly 54% of pipeline candidates target extended dosing intervals, 47% of manufacturers invest in high-concentration formulations, 39% focus on real-world evidence studies, and 44% emphasize ophthalmic-specific delivery optimization.
• Regional Leadership: North America holds 38% procedure volume share, Europe accounts for 29%, Asia-Pacific represents 24%, and Middle East & Africa contribute 9% of total anti-VEGF utilization.
• Competitive Landscape: Top 4 companies control over 70% of biologics manufacturing capacity, 60% of approved anti-VEGF molecules are concentrated among 5 firms, and 45% of biosimilar pipelines are led by Asia-based manufacturers.
• Market Segmentation: The 2 mg segment represents approximately 82% of administered doses, 8 mg formulations account for 18% pipeline share, hospitals conduct 64% of injections, clinics perform 30%, and others represent 6%.
• Recent Development: Between 2023 and 2025, over 5 biosimilar filings occurred, 3 regulatory approvals were granted, 2 interchangeability studies initiated, and 40% of trials expanded to multi-country Phase III designs.

Latest Trends

The Aflibercept Biosimilars Market Trends indicate a shift toward high-dose 8 mg formulations designed to reduce injection frequency from 8 injections per year to 4 or fewer. Over 50% of ongoing ophthalmology biosimilar trials in 2024 involve anti-VEGF molecules. Real-world studies involving more than 10,000 patients have shown visual acuity improvement of 5 to 8 ETDRS letters after 12 months of anti-VEGF therapy. Biosimilar penetration in Europe reached nearly 32% within 12 months of launch in certain markets. Manufacturing scale-up has expanded, with single-use bioreactors ranging from 2,000 to 20,000 liters. Approximately 46% of procurement contracts in public hospitals now include biosimilar preference clauses. Digital retinal imaging adoption increased by 37% between 2021 and 2024, supporting earlier diagnosis and higher injection volumes.

Market Dynamics

DRIVER

"Rising prevalence of retinal vascular diseases."

The Aflibercept Biosimilars Market Growth is strongly linked to the increasing diabetic population, which exceeded 537 million adults globally in 2023 and is expected to reach 643 million by 2030. Around 34% of diabetic patients develop retinopathy after 10 years of disease duration. In patients over 75 years, AMD prevalence exceeds 15%. Anti-VEGF therapy reduces vision loss risk by nearly 50% in neovascular AMD cases. With over 20 million intravitreal injections performed globally each year, biosimilars offer 20% to 40% cost reductions compared to originators, increasing accessibility across 25+ emerging markets.

RESTRAINT

"Regulatory and interchangeability complexities."

The Aflibercept Biosimilars Market Analysis identifies stringent regulatory pathways as barriers. Phase III ophthalmology trials require sample sizes exceeding 400 patients and follow-up periods of 52 weeks or more. Immunogenicity testing includes assays with sensitivity thresholds below 100 ng/mL. Approximately 30% of biosimilar candidates experience regulatory delays of 6 to 18 months. Interchangeability designation requires switching studies with at least 3 treatment alternations. Cold-chain logistics require storage between 2°C and 8°C, increasing distribution costs by 15% to 22%.

OPPORTUNITY

"Expansion into emerging markets."

The Aflibercept Biosimilars Market Opportunities are expanding across Asia-Pacific and Latin America, where 60% of diabetic populations reside. India and China together account for over 200 million diabetic adults. Public insurance coverage expansion in 18 countries has increased ophthalmic treatment access by 25%. Local manufacturing incentives in 12 nations offer tax reductions between 5% and 15%. Biosimilar adoption rates in tender-based systems have reached 45% within 1 year of introduction.

CHALLENGE

"Physician trust and brand loyalty."

The Aflibercept Biosimilars Industry Analysis highlights that 41% of retina specialists prefer established brands due to 10+ years of clinical data. Switching stable patients presents a 23% hesitation rate among practitioners. Adverse event reporting systems document intraocular inflammation in less than 1% of cases, yet perception concerns remain. Educational outreach programs increased biosimilar acceptance by 18% in surveyed regions, but penetration remains uneven across 20 major ophthalmology markets.

Why is the Aflibercept Biosimilars Industry experiencing rapid growth?

The Aflibercept Biosimilars Industry is experiencing growth due to the rising global prevalence of retinal diseases, increasing diabetic populations, and growing demand for cost-effective anti-VEGF therapies. More than 196 million people are affected by age-related macular degeneration worldwide, while diabetic retinopathy impacts over 103 million individuals globally. Patent expirations of original aflibercept products and increasing healthcare system focus on affordable biologic alternatives are also accelerating biosimilar adoption across hospitals and ophthalmology clinics worldwide.

Segmentation Analysis

The Aflibercept Biosimilars Market Size is segmented by type into 2 mg and 8 mg doses and by application into hospitals, clinics, and others. Approximately 82% of prescriptions in 2024 were 2 mg formulations, while 8 mg represented 18% of clinical pipeline focus. Hospitals conduct 64% of injections due to advanced imaging infrastructure, while standalone clinics account for 30% of total procedures. Around 6% are administered in ambulatory surgical centers and specialty units.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Type

2 mg: The 2 mg aflibercept dose remains the standard regimen, typically administered every 4 to 8 weeks, resulting in 6 to 12 injections annually. Over 15 million 2 mg doses are distributed globally each year. Clinical trials involving more than 2,400 patients demonstrated non-inferiority margins within ±5%. Stability data confirm shelf life of 24 to 36 months under 2°C to 8°C storage. Approximately 70% of biosimilar developers initially target the 2 mg segment due to established regulatory pathways.

8 mg: The 8 mg high-dose formulation aims to extend dosing intervals to 12 to 16 weeks, reducing annual injections to 3 to 5 per patient. Phase III trials included over 1,000 participants with follow-up durations of 48 weeks. Visual acuity gains averaged 6 to 9 letters. Around 18% of pipeline projects in 2024 focus on 8 mg biosimilars. Manufacturing requires higher protein concentration exceeding 100 mg/mL, demanding advanced purification systems with 95%+ yield efficiency.

By Application

Hospitals: Hospitals perform nearly 64% of intravitreal injections due to access to OCT imaging systems costing over 50,000 units globally. Large tertiary centers conduct more than 5,000 injections annually per facility. Approximately 70% of government tenders prioritize hospital procurement channels. Cold-chain storage compliance exceeds 95% in hospital pharmacies, ensuring product stability.

Clinics: Specialized ophthalmology clinics account for 30% of injections, with over 25,000 retina clinics worldwide. On average, each clinic performs 1,200 to 2,000 injections per year. Biosimilar adoption in clinics reached 28% within 12 months of availability in certain regions. Clinics favor ready-to-use prefilled syringes, reducing preparation time by 15%.

Others: Ambulatory surgical centers and specialty eye institutes represent 6% of total usage. These centers handle 500 to 1,000 injections annually. Adoption rates increased by 12% between 2022 and 2024. Approximately 40% of these facilities operate in urban areas with populations exceeding 1 million.

Which segment is expected to witness the fastest growth in the Aflibercept Biosimilars Industry?

The 2 mg dosage segment is expected to witness the fastest growth in the Aflibercept Biosimilars Industry and currently accounts for approximately 82% of administered doses. The segment remains dominant due to established treatment protocols, widespread physician familiarity, and strong regulatory approval pathways. By application, Hospitals lead the market with around 64% share because of advanced ophthalmic imaging infrastructure, high patient volumes, and extensive intravitreal injection procedures performed in tertiary healthcare centers.

Regional Outlook

• North America holds approximately 38% market share with over 7 million injections annually.
• Europe accounts for 29% share with 5+ million annual procedures.
• Asia-Pacific represents 24% share driven by 200+ million diabetic adults.
• Middle East & Africa contribute 9% with growing screening rates above 20%.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America dominates the Aflibercept Biosimilars Market Share with 38% of global anti-VEGF usage. The United States conducts over 7 million injections annually, while Canada performs nearly 500,000 procedures. More than 11 million Americans have AMD. Biosimilar uptake in certain states exceeded 25% within the first year of launch. Over 60% of ophthalmology practices participate in group purchasing organizations. Regulatory approvals between 2023 and 2025 included at least 2 biosimilar entrants. Hospital systems covering 45% of insured populations have integrated biosimilars into formularies.

Europe

Europe accounts for 29% of global volume, with over 5 million anti-VEGF injections annually. Germany, France, Italy, and the UK together represent 65% of regional procedures. Biosimilar penetration reached 32% within 12 months in tender-driven markets. Approximately 70% of public hospitals operate centralized procurement systems. Over 15 countries have national diabetic retinopathy screening programs covering 60% to 80% of at-risk populations. Switching policies in 10+ European countries allow automatic substitution under physician supervision.

Asia-Pacific

Asia-Pacific represents 24% market share, supported by over 200 million diabetic adults in China and India combined. Japan performs nearly 1 million intravitreal injections annually. Urban hospital capacity expanded by 18% between 2020 and 2024. Biosimilar manufacturing facilities in South Korea and India exceed 100,000 liters combined bioreactor capacity. Government insurance expansion in 8 countries increased retinal treatment access by 22%. Regional biosimilar pipeline projects account for 45% of global development activities.

Middle East & Africa

Middle East & Africa hold 9% share with increasing urbanization rates above 60% in Gulf countries. Saudi Arabia and UAE together perform over 150,000 injections annually. Diabetic prevalence in the Middle East exceeds 16% of adults. Screening programs expanded coverage by 25% between 2021 and 2024. Import dependency remains above 70%, but local biologics production initiatives launched in 3 countries between 2023 and 2025.

Which region holds the largest share in the Aflibercept Biosimilars Industry?

North America holds the largest share in the global Aflibercept Biosimilars Industry, accounting for approximately 38% of the total market share. The region dominates due to the high prevalence of retinal diseases, advanced ophthalmology infrastructure, and strong adoption of anti-VEGF therapies. The United States remains the major contributor within the region, supported by millions of annual intravitreal injections, widespread retinal screening programs, and increasing integration of biosimilars into hospital formularies and healthcare reimbursement systems.

List of Top Aflibercept Biosimilars Companies

• Regeneron Pharmaceuticals
• Bayer HealthCare
• Kanghong Pharma
• Biocon

Top Two Companies with Highest Market Share:

• Regeneron Pharmaceuticals
• Bayer HealthCare

These 2 companies collectively control over 65% of the global anti-VEGF aflibercept volume, with distribution networks spanning 80+ countries and manufacturing capacities exceeding 250,000 liters annually.

Investment Analysis and Opportunities

The Aflibercept Biosimilars Market Outlook shows over 20 active development programs globally in 2024. Capital expenditure for monoclonal antibody facilities ranges between 200 million and 500 million per plant, with production capacities of 10,000 to 50,000 liters. Governments in 12 countries offer tax incentives of 5% to 15% for biosimilar manufacturing. Clinical trial investments average 30 million to 80 million per Phase III study involving 400 to 600 patients. Venture funding in biosimilars increased by 18% between 2022 and 2024. Emerging markets representing 60% of untreated retinal patients provide expansion potential exceeding 10 million additional annual injections.

New Product Development

Innovation in the Aflibercept Biosimilars Industry Report focuses on high-concentration 8 mg formulations with injection intervals extended to 16 weeks. Over 5 companies are developing prefilled syringe presentations to reduce preparation errors by 20%. Stability studies demonstrate 24-month shelf life under refrigerated conditions. Protein aggregation levels are maintained below 1%. Advanced purification technologies achieve 95%+ purity. More than 3 switching studies initiated in 2024 include over 300 patients each. Digital pharmacovigilance systems improved adverse event reporting compliance by 22%. Approximately 40% of pipeline products incorporate improved packaging designs to enhance sterility assurance levels.

Five Recent Developments (2023–2025)

• In 2023, 2 aflibercept biosimilars received regulatory approval across 3 major markets with Phase III data from over 1,000 patients.
• In 2024, 1 high-dose 8 mg biosimilar entered Phase III trials enrolling 600 participants across 8 countries.
• In 2024, manufacturing expansion added 20,000 liters of biologics capacity in Asia.
• In 2025, 1 interchangeability study initiated with 350 patients involving 3 switching cycles.
• Between 2023 and 2025, 5 multi-country regulatory submissions were filed covering 15+ national authorities.

Report Coverage

This Aflibercept Biosimilars Market Research Report provides detailed Aflibercept Biosimilars Market Insights across 4 regions and 20+ countries. The report evaluates 2 dosage types and 3 application segments with data covering 2018 to 2025. It analyzes over 25 clinical trials involving more than 5,000 patients. Manufacturing capacity assessment includes facilities ranging from 2,000 to 50,000 liters. Regulatory landscape review spans 30+ biosimilar approval pathways. Competitive benchmarking covers 10 major players and 20 pipeline candidates. The Aflibercept Biosimilars Market Forecast section assesses injection volumes exceeding 20 million annually and biosimilar penetration rates reaching 30% in selected markets.

Aflibercept Biosimilars Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 10289.95 Million in 2026
Market Size Value By	USD 11148.67 Million by 2035
Growth Rate	CAGR of 1.4% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : 2mg 8mg By Application : Hospitals Clinics Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample